Vyne Therapeutics Inc.
13F holders, Q1 2024 (March 31)30holders
3famous investors
$2.92avg. 13F price*
At the end of Q1 2024, 30 institutions reported holding Vyne Therapeutics Inc. in their 13F filings. The largest holders were Cormorant Asset Management, LP ($4.3M), Citadel Advisors ($3.6M) and Eventide Asset Management, LLC ($3.1M). 3 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1.3M |
| Exits | 6 | $1.8M |
Ownership 30 holders
| Cormorant Asset Management, LP | 0.19% | No change | 1,394,336 | $4.3M |
| Citadel Advisors | 0.00% | No change | 1,181,088 | $3.6M |
| Eventide Asset Management, LLC | 0.05% | No change | 1,394,336 | $3.1M |
| Parkman Healthcare Partners LLC | 0.26% | No change | 696,470 | $2.1M |
| DSC Advisors, L.P. | 3.45% | No change | 696,465 | $2.1M |
| Palo Alto Investors LP | 0.15% | No change | 445,434 | $1.4M |
| AlphaCentric Advisors LLC | 0.82% | Reduce -33.4% | 445,000 | $1.4M |
| Exome Asset Management LLC | 1.09% | Add +251.8% | 415,434 | $1.3M |
| Schonfeld Strategic Advisors LLC | 0.01% | New | 219,800 | $675K |
| Royal Bank of Canada | 0.00% | Add +13763.4% | 175,372 | $538K |
| ADAR1 Capital Management, LLC | 0.09% | New | 110,091 | $338K |
| Geode Capital Management, LLC | 0.00% | Add +13.2% | 106,775 | $328K |
| Prelude Capital Management, LLC | 0.02% | Reduce -19.9% | 94,600 | $290K |
| Silverarc Capital Management, LLC | 0.07% | New | 86,383 | $265K |
| Renaissance Technologies | 0.00% | Add +73.8% | 80,576 | $247K |
| Vanguard Group Inc. | 0.00% | Add +40.4% | 69,633 | $214K |
| Susquehanna International Group, LLP | 0.00% | No change | 60,323 | $185K |
| BlackRock Inc. | 0.00% | Reduce -5.7% | 44,618 | $137K |
| Northern Trust Corp. | 0.00% | No change | 36,951 | $113K |
| Virtu Financial LLC | 0.00% | New | 16,199 | $50K |
| State Street Corp. | 0.00% | No change | 11,665 | $36K |
| Millennium Management | 0.00% | Reduce -36.4% | 10,990 | $34K |
| Bank of America Corp. | 0.00% | Reduce -21.5% | 2,187 | $7K |
| Morgan Stanley | 0.00% | No change | 1,868 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +57.1% | 1,241 | $4K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 1,041 | $3K |
| Russell Investments Group, Ltd. | 0.00% | No change | 187 | $574 |
| Wells Fargo & Company | 0.00% | Add +1.2% | 174 | $535 |
| JPMorgan Chase & Co. | 0.00% | Add +15.8% | 169 | $520 |
| UBS Group AG | 0.00% | Reduce -98.1% | 16 | $49 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.